SS Innovations International Inc. Common Stock
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems. The company also develops NADI " Automated Coronary Anastomotic Connector, a micro stapling device; SSi Multi-Fire Clip Applier, a cartridge-based clip applicator; SSi Robotic Stapler; SSi Maya " XR Pre-Operative Simulator, a robotic surgery platform; SSi Holographic Anatomy, an augmented reality tool; SSi Chitrasa " Advanced DICOM Viewer, an AI enabled application viewer; and SSi Mixed Reality Headset, a medical-grade device. In addition, it offers instrument tips, including forceps, scissors, electrocautery tools, scalpels, and other surgical tools. Further, the company provides accessory products, such as sterile drapes, 3d stereo endoscopes, cannulas, and seals, as well as tele proctoring and telesurgery products. Additionally, it offers installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring services. The company sells its products through direct sales organizations and distributor networks. SS Innovations International, Inc. is headquartered in Gurugram, India.
Open SSII dashboard ↗Zai Lab Limited American Depositary Shares
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Open ZLAB dashboard ↗